netFormulary Oxfordshire Clinical Commissioning Group NHS
 Formulary Chapter 13: Skin - Full Chapter
13.14  Expand sub section  dermatology specials
13.14.01  Expand sub section  Emollients and barriers
13.14.02  Expand sub section  Steroid combinations
13.14.03  Expand sub section  Tars
13.14.04  Expand sub section  Ichthammol to top
13.14.05  Expand sub section  Dithranol preparations
13.14.06  Expand sub section  Keratolytics
13.14.07  Expand sub section  Miscellaneous
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to children's BNF
click to search
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England

Traffic Light Status Information

Status Description


Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   


Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   


Brown: Medicines which should only be prescribed in restricted circumstances.  


Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used